EMA Authorised: Steglatro (ertugliflozin l-pyroglutamic acid) — Merck Sharp & Dohme B.V.

View source ↗

Summary

The EMA authorised Steglatro (ertugliflozin l-pyroglutamic acid) from Merck Sharp & Dohme B.V. for type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• STEGLATRO (ertugliflozin)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Merck Sharp & Dohme B.V.. Decision date: 21/11/2025